Inicio › Cáncer de pulmón de células no pequeñas › Indiana

Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Indiana

49 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Indiana.

Ciudades en Indiana

Texto oficial del estudio (inglés)

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Northwest Cancer Centers, P.C., Dyer

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07361510

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Northwest Cancer Center - Crown Point, Crown Point
Northwest Oncology LLC, Dyer
Parkview Regional Medical Center, Fort Wayne
y 7 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT04267848

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Fort Wayne Medical Oncology and Hematology, Fort Wayne

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07361497

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Northwest Cancer Center - Crown Point, Crown Point
Northwest Oncology LLC, Dyer
Saint Mary Medical Center, Hobart
y 4 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07388524

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Parkview Comprehensive Cancer Center /ID# 271879, Fort Wayne

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06772623

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

IU Health West Hospital, Avon
IU Health North Hospital, Carmel
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06498635

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Indiana University Health Arnett Cancer Center ( Site 0116), Lafayette

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07190248

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Franciscan Health ( Site 0219), Indianapolis

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06623422

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Community Health Network, Inc, Indianapolis
Community Health Network, Inc., Indianapolis
Community Health Network, Inc., Indianapolis

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07222566

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Franciscan Health, Munster

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07154290

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Fort Wayne Medical Oncology and Hematology, Fort Wayne
Investigative Clinical Research of Indiana, LLC, Noblesville

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06667076

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Parkview Research Center /ID# 277651, Fort Wayne

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07155187

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Parkview Research Center at Parkview Regional Medical Center ( Site 0089), Fort Wayne
Indiana University Health Arnett Cancer Center ( Site 0076), Lafayette

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06312137

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
Franciscan Health, Indianapolis

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06890598

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Noblesville

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT06357533

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Community Health Network, Indianapolis

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06128551

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne
Indiana University Health University Hospital, Indianapolis

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06712316

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Northwest Cancer Centers, P.C., Dyer
Parkview Research Center at Parkview Regional Medical Center, Fort Wayne

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06875310

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Indiana University (IU) Health - Multi-D Oncology Clinic, Indianapolis

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07488676

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Fort Wayne

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Indianapolis

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06767514

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Goshen Center for Cancer Care, Goshen

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT04613596

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT07761910

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Indiana University Simon Comprehensive Cancer Center, Indianapolis

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06625775

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Franciscan Health, Indianapolis
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06119581

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

IU Simon Cancer Center, Indianapolis

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT06465069

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Community Health Network, Indianapolis

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT07027514

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Research Site, Fort Wayne

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 ago 2026 · NCT06350097

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Community Health Network, Indianapolis

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 ago 2026 · NCT06586515

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #4, Indianapolis

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT05176483

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Fort Wayne Medical Oncology and Hematology, Fort Wayne

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 jul 2026 · NCT06150664

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

UChicago Medicine - Northwest Indiana, Crown Point
Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
Community Health Network, Inc, Indianapolis
y 3 más

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 jul 2026 · NCT04389632

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Parkview Packnett Family Cancer Institute, Fort Wayne
Franciscan Health Indianapolis, Indianapolis

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 jun 2026 · NCT06216301

A Study of LY4175408 in Participants With Advanced Cancer

Community Health Network, Indianapolis

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jun 2026 · NCT07046923

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne
Community Health Network, Inc. /ID# 243011, Indianapolis

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jun 2026 · NCT05005403

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 may 2026 · NCT06116682

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT04317534

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

ReclutandoFase 2

18 Minutes · Todos los sexos · Actualizado el 5 may 2026 · NCT06031688

A Study of VET3-TGI in Patients With Solid Tumors

Community Health Network, Indianapolis

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 7 abr 2026 · NCT06444815

De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.